Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
In a new study, researchers have found that measuring the walking speed of a person living with idiopathic pulmonary fibrosis (IPF) over 4 metres can help predict their health status over the following year.
IPF is a chronic condition that causes progressive scarring in the lungs, meaning lung function reduces over time and breathing becomes more and more difficult.
This study, published in the European Respiratory Journal, aimed to find out if the physical performance of someone living with IPF could predict the likelihood of hospitalization and whether a person would still be alive in 1 year. This is important because IPF disease progression varies a lot between different people, making it difficult to plan for the future.
Researchers measured the lung function and 4-metre gait speed (walking speed over 4 metres) of 130 people who had just been diagnosed with IPF, on a flat, open course as a quick and easy way to assess their physical ability. Over the next year, emergency hospital visits and survival status of these patients were recorded.
The results show that patients with faster 4-metre gait speeds were more likely to survive over the study period. They were also less likely to be admitted to hospital, and those that were hospitalized had a longer time before their first hospital admission than patients with a slower 4-metre gait speed.
The researchers concluded that the 4-metre gait speed test could be a useful test to help healthcare professionals assess newly diagnosed IPF patients. They also suggest that it could be a useful test for clinical trials.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
No description